Clarivate plc: completes sale of life sciences and healthcare for $500,000,000

What happened Clarivate Plc reported it completed the previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC on Oct 6, 2026 pursuant to a Stock and Asset Purchase Agreement dated July 3, 2026. At closing, Buyer paid cash consideration of $500,000,000 to a wholly-owned subsidiary of Clarivate, issued an unsecured senior note in the principal amount of $75,000,000 to a wholly-owned subsidiary of Clarivate, and agreed to deferred consideration of $25,000,000 payable upon the latest of specified transition or payment milestones or Jan 31, 2028.

Key details

• Cash consideration of $500,000,000, subject to customary adjustments for cash, indebtedness, working capital and transaction expenses.
• Buyer issued an unsecured senior note with aggregate principal amount of $75,000,000 to a Clarivate subsidiary.
• Deferred consideration of $25,000,000 payable upon the later of (x) 20 business days after completion of transition services, (y) 20 business days after receipt of final payment for those services, or (z) Jan 31, 2028 (but no later than Jan 31, 2028).
• Upon closing, Henry Levy, Clarivate’s president, life sciences & healthcare, terminated employment with a Clarivate subsidiary and entered a separation agreement that provides payments and benefits set forth in his previously disclosed retention agreement.
• Clarivate issued a press release dated Oct 6, 2026 announcing the completion and expects to file unaudited pro forma condensed consolidated financial information in a Form 8-K no later than Oct 13, 2026.

Why it may matter This report was filed under Item 2.01 (completion of acquisition or disposition of assets) covering the sale terms and consideration, Item 5.02 (departure of certain officers) reporting Henry Levy’s termination and separation agreement, and Item 8.01 reporting the press release. The filing does not show why the insider traded or why the company acted.